Please login to the form below

Not currently logged in
Email:
Password:

UK Prix Galien opens for entries

Pharma R&D accolades will include a new real world evidence category

Prix Galien 2014 winner Novartis 
Pictured: Novartis pick up the 2014 Innovative Product award

Entries have opened for the 2016 UK Prix Galien Awards, which commend pharmaceutical research and development and celebrate outstanding efforts to improve the human condition through the development of novel, high-value medicines.

Established in 1970, the next outing for the bi-annual prizes will include a new real world evidence category, alongside their well-established accolades for innovative products and orphan product.

The 2014 UK Prix Galien was won by Bexserothe first ever vaccine to treat invasive meningococcal disease, and Sirturo, the first TB medication to be approved in four decades.

The Prix Galien is recognised in 17 countries across Europe and North America, with presences in emerging markets in Asia and Latin America expected soon. The UK Prix Galien franchise is now owned by ValueBase, whose experienced team has a long-standing affiliation with the awards. The 2016 UK judging panel is once again led by Professor Sir Michael Rawlins, chair of the MHRA and founding chair of NICE from 1999 to 2014.

Previous UK Prix Galien winners include well-known brands such as Viagra, Herceptin, Glivec, Xolair, Cervarix and Gardasil. More recent winners, such as Xarelto, Incivo and Victrelis, show how pharmaceutical innovation is helping to transform healthcare services and improve public health.

Registration for entries for the 2016 Awards will close on 29 February 2016, with final submissions due by 29 April 2016, as part of a process that culminates in a ceremony at the House of Commons in September 2016.

For further details on the awards and the entry process visit www.prixgalien.co.uk 

Article by
Dominic Tyer

8th December 2015

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
M3 (EU)

M3 is the world’s largest network of verified doctors with over 6 million members across key markets; our closed and...

Latest intelligence

The doctor will text you now: Why healthcare providers cannot underestimate the importance of communicating change
Healthcare communication needs to switch from ‘transmit’ to ‘receive’, listening to what patients need and embracing the plethora of communication tools wholeheartedly....
How to innovate and influence people in times of misinformation
The pandemic has shown that public trust in promising new medical technologies is far from a given. Senior Writer Tom Vandyck at StoneArch, a member of Fishawack delves into the...
Could femtech be the answer to the gender health gap?
Here, we discuss the phenomenon of femtech, an industry that puts women’s experiences of lifestyle and health front and centre. We highlight some of the major players in the industry,...